321 related articles for article (PubMed ID: 19860627)
21. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404).
Cho H; Yoon DH; Shin DY; Koh Y; Yoon SS; Kim SJ; Do YR; Lee GW; Kwak JY; Park Y; Kim MK; Kang HJ; Yi JH; Yoo KH; Lee WS; Park BB; Jo JC; Eom HS; Kim HJ; Jeong SH; Won YW; Sohn BS; Kwon JH; Suh C; Kim WS
Cancer Res Treat; 2023 Apr; 55(2):684-692. PubMed ID: 36596727
[TBL] [Abstract][Full Text] [Related]
22. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
23. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
25. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
Advani RH; Skrypets T; Civallero M; Spinner MA; Manni M; Kim WS; Shustov AR; Horwitz SM; Hitz F; Cabrera ME; Dlouhy I; Vassallo J; Pileri SA; Inghirami G; Montoto S; Vitolo U; Radford J; Vose JM; Federico M
Blood; 2021 Jul; 138(3):213-220. PubMed ID: 34292324
[TBL] [Abstract][Full Text] [Related]
27. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.
Xu P; Yu D; Wang L; Shen Y; Shen Z; Zhao W
Ann Hematol; 2015 Feb; 94(2):239-47. PubMed ID: 25193354
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
29. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
[TBL] [Abstract][Full Text] [Related]
30. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
31. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
32. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
33. [Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Qin Y; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Liu XF; Liu P; Yang S; Zhou LQ; Han XH; Yao JR
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):448-51. PubMed ID: 20819488
[TBL] [Abstract][Full Text] [Related]
34. Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified.
Zhang XM; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Zhou LQ; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1051-6. PubMed ID: 23021436
[TBL] [Abstract][Full Text] [Related]
35. Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma.
Kameoka Y; Takahashi N; Itou S; Kume M; Noji H; Kato Y; Ichikawa Y; Sasaki O; Motegi M; Ishiguro A; Tagawa H; Ishizawa K; Ishida Y; Ichinohasama R; Harigae H; Sawada K
Int J Hematol; 2015 Jun; 101(6):536-42. PubMed ID: 25739382
[TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
37. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
[TBL] [Abstract][Full Text] [Related]
38. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
[TBL] [Abstract][Full Text] [Related]
39. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.
Tokunaga T; Shimada K; Yamamoto K; Chihara D; Ichihashi T; Oshima R; Tanimoto M; Iwasaki T; Isoda A; Sakai A; Kobayashi H; Kitamura K; Matsue K; Taniwaki M; Tamashima S; Saburi Y; Masunari T; Naoe T; Nakamura S; Kinoshita T
Blood; 2012 Mar; 119(12):2837-43. PubMed ID: 22308294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
